文献速递系统性红斑狼疮

EuroLupus与国立卫生研究院环磷酰胺方案在儿童起病增殖性狼疮肾炎中的肾脏缓解结局比较

Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood-Onset Proliferative Lupus Nephritis.
PubMed 文献 · Arthritis Rheumatol · 2024-01-11

在北美11个儿科中心开展的回顾性队列研究纳入145例儿童起病增殖性狼疮肾炎患者(EuroLupus方案58例、NIH方案87例),比较两种环磷酰胺方案的肾脏缓解。多变量调整后,12个月完全肾脏缓解与至少部分肾脏缓解在两种方案间均无显著关联(OR分别为0.76和1.35),研究未能证明NIH方案优于EuroLupus方案,但需未来前瞻性研究。

要点

  • 多变量调整后,12个月完全肾脏缓解EuroLupus方案与NIH方案相比OR=0.76(95%CI 0.29-1.98),无显著关联。
  • 12个月至少部分肾脏缓解两种方案相比OR=1.35(95%CI 0.57-3.19),无显著关联。
  • EuroLupus组起始环磷酰胺治疗时年龄更大、病程更长、复发或难治性狼疮肾炎更多见。

核心结论

  • 研究未能证明NIH环磷酰胺方案在儿童起病增殖性狼疮肾炎中优于EuroLupus方案,但需要未来前瞻性结局研究。

研究设计与样本

  • 在北美11个儿科中心开展的回顾性队列研究,纳入145例儿童起病增殖性狼疮肾炎患者(EuroLupus方案58例、NIH方案87例),从电子病历提取基线及环磷酰胺治疗开始后3、6、12个月的数据。

主要发现

  • EuroLupus组与NIH组相比,起始当前环磷酰胺治疗时平均年龄更大、病程更长、复发或难治性狼疮肾炎更常见。
  • 多变量调整后,12个月达到完全肾脏缓解与环磷酰胺方案无显著关联(EuroLupus方案相对于NIH方案的OR=0.76,95%CI 0.29-1.98)。
  • 多变量调整后,12个月达到至少部分肾脏缓解与环磷酰胺方案无显著关联(OR=1.35,95%CI 0.57-3.19)。

局限性

  • 原文结论指出需要未来前瞻性结局研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We compared clinical characteristics and renal response in patients with childhood-onset proliferative lupus nephritis (LN) treated with the EuroLupus versus National Institutes of Health (NIH) cyclophosphamide (CYC) regimen. METHODS: A retrospective cohort study was conducted at 11 pediatric centers in North America that reported using both CYC regimens. Data were extracted from the electronic medical record at baseline and 3, 6, and 12 months after treatment initiation with CYC. To evaluate the adjusted association between CYC regimen (EuroLupus vs NIH) and renal response over time, generalized estimating equations with a logit link were used. An interaction between time and CYC regimen was included, and a contrast between CYC regimens at 12 months was used to evaluate the primary outcome. RESULTS: One hundred forty-five patients (58 EuroLupus, 87 NIH) were included. EuroLupus patients were on average older at the start of current CYC therapy, had longer disease duration, and more commonly had relapsed or refractory LN compared with the NIH group. After multivariable adjustment, there was no significant association between CYC regimen and achieving complete renal response at 12 months (odds ratio [OR] of response for the EuroLupus regimen, reference NIH regimen: 0.76; 95% confidence interval [CI] 0.29-1.98). There was also no significant association between CYC regimen and achieving at least a partial renal response at 12 months (OR 1.35, 95% CI 0.57-3.19). CONCLUSION: Our study failed to demonstrate a benefit of the NIH regimen over the EuroLupus CYC regimen in childhood-onset proliferative LN. However, future prospective outcome studies are needed.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wang CS, Sadun RE, Zhou W, et al. Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood-Onset Proliferative Lupus Nephritis. Arthritis Rheumatol. 2024. PMID: 37800549. doi:10.1002/art.42725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。